Preserving double equipoise in living donor liver‐kidney transplantation for primary hyperoxaluria type 1
Gomathy Narasimhan, Sanjay Govil, Rajesh Rajalingam, Chandrasekaran Venkataraman, Naresh P. Shanmugam, Mohamed Rela – 15 May 2015
Living donor liver transplantation for Echinococcus Alveolaris: single‐center experience
Fatih Ozdemir, Volkan Ince, Bora Barut, Asim Onur, Cuneyt Kayaalp, Sezai Yilmaz – 15 May 2015 – Echinococcus alveolaris (EA) causes a hepatic zoonotic infection and behaves like a malignant tumor during invasion. Liver transplantation (LT) is the only curative treatment option for this unresectable disease. Here, we share our experience with living donor liver transplantation (LDLT) due to EA from the time between March 2002 and November 2014 at the Liver Transplantation Institute of İnönü University.
Liver transplantation after endoscopic ultrasound–guided cholecystoduodenostomy for acute cholecystitis: A note of caution
Todd H. Baron, Ian S. Grimm, David A. Gerber – 15 May 2015
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma patients awaiting liver transplantation
Tim Cross, Adli Metussin – 15 May 2015
Acute kidney injury after orthotopic liver transplantation using living donor versus deceased donor grafts: A propensity score–matched analysis
Ibtesam A. Hilmi, Daniela Damian, Ali Al‐Khafaji, Tetsuro Sakai, Joseph Donaldson, Daniel G. Winger, John A. Kellum – 15 May 2015 – Acute kidney injury (AKI) is a common complication after liver transplantation (LT). Few studies investigating the incidence and risk factors for AKI after living donor liver transplantation (LDLT) have been published. LDLT recipients have a lower risk for post‐LT AKI than deceased donor liver transplantation (DDLT) recipients because of higher quality liver grafts.
Reply
Alessandro Cucchetti, Benjamin Djulbegovic – 14 May 2015
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
Francesca Ceccherini Silberstein, Velia Chiara Di Maio, Marianna Aragri, Marco Ciotti, Valeria Cento, Carlo Federico Perno – 14 May 2015
Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects
Grace Lai‐Hung Wong, Yee‐Kit Tse, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Kelvin Kam‐Fai Tsoi, Henry Lik‐Yuen Chan – 14 May 2015 – Widespread and long‐term use of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a real‐life setting. We aimed to determine the risks of renal and bone side effects in patients receiving or who have received NAs as CHB treatment. A territory‐wide cohort study using the database from Hospital Authority, the major provider of medical services in Hong Kong, was conducted.
Comment on “when to perform hepatic resection for intermediate‐stage hepatocellular carcinoma”
Lisa A. Spacek, Steven F. Solga – 14 May 2015